Loading...
•
Dec 31, 2025
Intellia Q4 2025 Earnings Report
Intellia reported fourth quarter 2025 results with higher collaboration revenue and a reduced net loss year-over-year.
Key Takeaways
Collaboration revenue increased to 23017000 in the fourth quarter of 2025, while net loss narrowed to 95786000 compared to 128898000 in the prior year period, driven by lower operating expenses.
Collaboration revenue rose to 23017000 from 12874000 year-over-year.
Research and development expenses decreased to 88652000 from 116877000.
Total operating expenses declined to 121727000 from 149321000.
Net loss improved to 95786000 compared to 128898000 in the prior year.
Revenue by Segment
Forward Guidance
The company expects its cash, cash equivalents and marketable securities of 605134000 as of December 31, 2025 to fund operations into the second half of 2027 and through the anticipated U.S. commercial launch of lonvo-z.
Positive Outlook
- Cash runway expected into the second half of 2027.
- HAELO Phase 3 topline data expected by mid-2026.
- Planned BLA submission for lonvo-z in the second half of 2026.
- Anticipated U.S. launch of lonvo-z in the first half of 2027.
- MAGNITUDE-2 clinical hold lifted and enrollment resuming.
Challenges Ahead
- Clinical hold remains in place for MAGNITUDE Phase 3 trial in ATTR-CM.
- Continued significant operating losses.
- High ongoing R&D expenses.
- Regulatory uncertainties related to clinical programs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...